Author

H. F. Moffett

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:mouse· 1 Assay:protein sequence· 1 Assay:proteomics· 1

Frequent Co-Authors

C. K. Harms· 1 shared J. Boonyaratankornkit· 1 shared J. J. Taylor· 1 shared K. S. Fitzpatrick· 1 shared L. J. Tait· 1 shared M. J. Lajoie· 1 shared M. R. Tooley· 1 shared S. M. Stull· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

C. K. Harms

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Safety switch optimization enhances antibody-mediated elimination of CAR T cells

T. B. Shabaneh, H. F. Moffett, S. M. Stull, T. Derezes, L. J. Tait, S. Park, S. R. Riddell, M. J. Lajoie

This study optimizes a safety switch for CAR T cells by enhancing EGFRt expression, leading to more effective antibody-mediated elimination.

bioRxiv · Aug 24, 2022 · PreprintBioengineering

B cells engineered to express pathogen-specific antibodies using CRISPR/Cas9 protect against infection

H. F. Moffett, C. K. Harms, K. S. Fitzpatrick, M. R. Tooley, J. Boonyaratankornkit, J. J. Taylor

This study uses CRISPR/Cas9 to engineer B cells with pathogen-specific antibodies, providing durable protection against RSV in immunocompromised hosts.

bioRxiv · Feb 6, 2019Immunology